Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tandem Diabetes Care ( (TNDM) ) has provided an announcement.
On May 16, 2025, Tandem Diabetes Care received CE mark approval for its Tandem Mobi insulin delivery system with Control-IQ+ technology. The company plans to pursue further regulatory and pre-commercial activities in the EU, aiming for commercial launches by the end of 2025.
The most recent analyst rating on (TNDM) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
Tandem Diabetes Care’s overall stock score reflects a challenging financial situation with significant profitability and cash flow issues, despite strong revenue growth. Technical indicators suggest a bearish trend, while valuation metrics highlight ongoing financial losses. However, the recent earnings call presents a more optimistic outlook with record sales and strategic initiatives, which could improve future performance.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
Tandem Diabetes Care operates in the medical device industry, specializing in insulin delivery systems. The company focuses on providing advanced diabetes management solutions, primarily targeting individuals with diabetes requiring insulin therapy.
Average Trading Volume: 1,908,033
Technical Sentiment Signal: Sell
Current Market Cap: $1.51B
See more insights into TNDM stock on TipRanks’ Stock Analysis page.